Biogen stops Phase II for returned IPF candidate

Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns.

Biogen Inc.

Read the full 270 word article

How to gain access

Continue reading with a
two-week free trial.